汇丰研究发表报告指，海吉亚医疗(06078.HK) 2024年业绩未达预期，营收按年增长9%，但净利下跌13%，低于市场及该行预期。公司股价在过去六个月累计调整32%，在对其医院扩张步伐转趋审慎之后，该行将公司2025至2026年的纯利预测下调介乎25%至27%。
该行认为股价调整已反映短期业务压力。汇丰研究预计，在现有管道支持下，公司2025年收入增长10%，净利增长15%。同时预期海吉亚医疗盈利见底回升，商业保险业务进展成潜在股价催化因素，维持“买入”评级，目标价由25元下调至19元。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-16 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.